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Abstract: The oxidation of low density lipoproteins (LDL) is regarded as a critical factor in the pathogenesis of athero-
sclerosis, especially the initial steps of the disease. In addition, other oxidative events have been shown to participate in
the progression of atherosclerosis and precipitation of cardiovascular events, through modulation of important compo-
nents of lesions of the vessel wall (smooth muscle cell proliferation, protease/antiprotease balance, endothelial functions).
Our recent studies have provided evidence that the enzyme gamma-glutamyltransferase (GGT), normally found in serum,
is often accumulated within the plaque environment in substantial amounts, and that this activity is a potential source of a
variety of prooxidant species. Concurrently, epidemiological research has conclusively documented that the serum levels
of GGT are an independent factor in prognosis of myocardial infarction and stroke in atherosclerotic patients. Several
signs suggest that the GGT appearing in plaque tissue may originate from the serum enzyme, which in facts associates
with the circulating lipoprotein fractions. Thus, data seem to point out that pathogenesis of atherosclerosis – and in par-
ticular of the events leading to progression of the disease and acute cardiovascular events – might include an as yet unex-
plored pathway, based on the prooxidant effects of gamma-glutamyltransferase accumulating as a result of LDL entry in
the vessel wall.
Keywords: Serum g-glutamyltransferase, atherosclerosis, atherosclerotic plaque, oxidative stress, glutathione, protein oxida-
tion.
INTRODUCTION
In dealing with atherosclerotic patients, much attention is
devoted to predicting which subjects will experience acute,
potentially fatal cardiovascular events. The focus is therefore
on the numerous factors capable of affecting plaque stability,
i.e. the pathophysiological, cellular and biochemical deter-
minants that have been shown to participate in the progres-
sion of atherosclerotic lesions. The understanding of these
factors would in fact allow the identification of high-risk
lesions, in which the pathological changes produced by the
disease process are more likely to result in plaque rupture,
thrombosis and the associated ischemic/necrotic sequelae;
establishing timely treatment for such lesions would clearly
represent a major advance in secondary prevention and ther-
apy.
Oxidative reactions occupy an important position among
factors of plaque progression and “destabilization” [1]. One
specific oxidative event – the oxidation of low density lipo-
protein (LDL) – had been highlighted by earlier studies as
the single crucial event in pathogenesis of atherosclerosis,
with special reference to the initiation of lesions. Subsequent
research has shown however that the implication of oxidative
processes may be considerably wider, extending to include
effects on several other important pathological changes oc-
curring in the diseased vessel wall. Thus, it has been
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shown that oxidants and redox reactions are involved in
stimulation of smooth muscle cell proliferation, contributing
to lesion thickness and expansion. The activities of matrix
metalloproteinases and of their inhibitors – major determi-
nants of plaque stability – are modulated through redox
changes in critical portions of their protein structure. Some
aspects of endothelial dysfunction [e.g. impairment of .nitric
oxide (NO) production, expression patterns and levels of
adhesion molecules] are also affected by oxidative events,
and several other redox-sensitive steps are present in signal
transduction, apoptotic cell death and platelet function.
Altogether, current experimental studies consistently
indicate that oxidation/reduction processes may be fre-
quently involved in the production of changes capable of
turning a mildly stenotic, silent plaque into a vulnerable,
symptomatic and potentially fatal lesion. A series of enzyme
activities, expressed by cellular elements present in the le-
sions (endothelium, phagocytes, smooth muscle cells, fibro-
blasts) have been proposed as sources of the oxidants in-
volved; these include NADPH-oxidases, NO-synthase, xan-
tine oxidase, myeloperoxidase, lipoxygenases and enzymes
of mitochondrial respiration. Non-enzymic prooxidants also
participate in the reactions, such as transition metals (iron,
copper) and lipid peroxides. However, the relative roles and
importance of each of the mentioned factors in the “oxida-
tive progression” of lesions have not been elucidated yet,
and are likely to depend on which aspect of the process is
being considered; the whole matter is in fact the subject for
extensive experimental research.
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g -GLUTAMYLTRANSFERASE (GGT) ACTIVITY: A
NOVEL MARKER OF ATHEROSCLEROSIS
Although best known as a reliable index of hepatobiliary
dysfunction and alcohol abuse [2], serum GGT levels have
been repeatedly proposed to play an independent role in
clinical evolution of cardiovascular diseases related with
atherosclerosis [3]. Several studies had documented that se-
rum GGT is associated with overall mortality and cardiovas-
cular events in both unselected populations [4-7] and patients
with ascertained coronary artery disease, independent of all
confounders including liver function and alcohol consump-
tion [8]. A recent prospective study, carried out in as many
as 163,944 adult subjects [9], has now rather conclusively
shown that serum GGT levels are an independent prognostic
factor for fatal events of chronic forms of coronary artery
disease, congestive heart failure and ischemic or hemor-
rhagic stroke. The finding was true for both sexes, with a
clear dose-response relationship and a stronger significance
as far as younger subjects were concerned.
The prognostic value of serum GGT activity for cardiac
death and non-fatal infarction had been previously docu-
mented in a prospective study of our own, including a six-
year follow-up of 469 patients with ischemic syndrome and
angiographically documented coronary artery disease [10].
In this study, the significance of serum GGT was more evi-
dent in a subset of patients prone to plaque complications,
i.e. characterized by the association of diffuse atherosclerosis
(multivessel disease) and a history of previous myocardial
infarction (approx. 36% of the whole population). The risk
was increasing using two different GGT cut-off values (25 or
40 U/l, both generally considered within the normal range),
the event excess being concentrated within the first three-
year period. The prognostic significance of serum GGT was
thus correlated with the diffusion of coronary artery disease,
and interestingly, the significance of serum GGT appeared to
depend on the instability of plaques, as indicated by the fact
that the prognostic value of GGT disappeared after revascu-
larization by angioplasty, a procedure thought to effect
plaque stabilization. The unfavourable prognosis signaled by
elevated serum GGT appeared thus to apply specifically to
patients with vulnerable plaques, suggesting that connections
of some kind may exist between GGT and the processes in-
volved in plaque stability [10].
It should be stressed that all of the studies mentioned
above refer to “normal” serum GGT, i.e. values within the
laboratory reference range, such as in the large prospective
study by Wannamethee et al. (7613 middle-aged men, with a
11-years follow-up), showing that GGT levels in the normal
range (top quintile of distribution) were strongly associated
with a significant increase in deaths from ischemic heart
disease [6]. Serum GGT was positively correlated with pre-
existing ischemic heart disease (IHD), diabetes mellitus,
antihypertensive medication, systolic and diastolic blood
pressure, total and high density lipoprotein (HDL) choles-
terol, heart rate and blood glucose. After adjustment for these
variables, elevated GGT (highest quintile, ³  24 U/l, vs. the
rest) was still associated with a significant increase in mor-
tality from all causes and from IHD. The increased risk of
IHD mortality was more marked for patients with evidence
of IHD at screening, particularly those with previous myo-
cardial infarction [6]. The increased mortality in men without
heart disease was obviously dependent on other causes; on
the other hand, the findings in ischemic patients again
pointed to a connection of serum GGT with unknown as-
pects of the underlying atherosclerotic coronary artery dis-
ease.
While the clinical studies mentioned above suggest an
implication of circulating GGT in the evolution of disease,
an indirect confirmation derives from additional evidence
obtained by histochemistry. Histochemical studies performed
in our laboratories showed that intense GGT activity is often
present in the intimal layers of human atherosclerotic le-
sions, where it is apparently expressed in CD68+ macro-
phage-derived foam cells [11, 12]. GGT-positive foam cells
were found to co-localize with immunoreactive oxidized
LDL [13], and catalytically active GGT could also be de-
tected in microthrombi adhering to the surface of atheromas
[14]. Whether GGT activity found in plaque tissue is actually
participating in the disease – or is rather an epiphenomenon
lacking specific significance – remains to be ascertained; at
least two questions arise: i) how could GGT activity affect
the progression of the disease, and ii) how are serum levels
of GGT related with the enzyme detectable in plaques?
FUNCTIONS OF g -GLUTAMYLTRANSFERASE
ACTIVITY – A DOUBLE-EDGED SWORD
The biochemical functions of GGT enzyme activity are
complex, and its overall physiological significance has not
been fully appreciated yet. Several aspects of GGT activity
are indeed capable of promoting effects of oxidative nature,
which in principle might contribute to progression of the
atherosclerotic process. Most of the knowledge about the
functions of GGT is concerned with the roles played by this
activity at the cellular level. High GGT levels are expressed
in kidney tubules, biliary epithelium and brain capillaries;
however, lower or trace levels are detectable in many more
cell types, e.g. blood cells, endothelium, and notably secre-
tory and absorptive cells [15]. Being located at the plasma
membrane level, GGT catalyzes the first step in the degrada-
tion of extracellular glutathione (GSH), i.e. the hydrolysis of
the gamma-glutamyl bond between glutamate and cysteine.
In this process GGT releases the dipeptide cysteinyl-glycine,
which is subsequently cleaved to cysteine and glycine by
plasma membrane dipeptidase activities; thus, GGT activity
provides cells first of all with a means for the recovery of
precursors needed to reconstitute the intracellular levels of
glutathione, the main cellular antioxidant (Fig. 1A). Novel
insights however have been prompted by studies showing the
ability of GGT to play a prooxidant role under selected con-
ditions. The key issue in this alternative function of GGT is
related to the reducing properties of GSH and the thiol me-
tabolites originating from GGT activity. Thiols – especially
when dissociated to their thiolate anion forms (R-S-) – can
effect the reduction of metal cations, e.g. iron and copper.
Electrons can then be transferred in turn from metal ions to
molecular oxygen, thus generating the reactive oxygen spe-
cies superoxide anion and hydrogen peroxide, both capable
of stimulating prooxidant reactions. The sequence – a true
“redox cycling” of metals [16] – can proceed with even
minimal concentrations of metal ions as long as the electron
donors (thiols) and electron acceptor (molecular oxygen) are
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available. In this way, and paradoxically, the ‘reducing’
abilities of thiols are eventually turned into overall ‘oxidiz-
ing’ effects. Stark et al. [17] were the first to propose that the
catabolism of GSH can play a prooxidant role under selected
conditions. These authors suggested that the GGT-mediated
cleavage of GSH – allegedly through the generation of the
more reactive thiol cysteinyl-glycine – could cause the re-
duction of ferric iron Fe(III) to ferrous iron Fe(II), thus
starting an iron-dependent redox-cycling process liable to
result in the production of reactive oxygen species (ROS)
and the stimulation of oxidative reactions (Fig. 1B). Subse-
quent studies from our and other laboratories have repeatedly
documented the production of ROS during the catabolism of
GSH mediated by cellular GGT. The biochemical processes
involved have been characterized (reviewed in [14]), and
some of the redox effects occurring at the cellular level have
been described, e.g. on the activation status of transcription
factors and apoptotic signalling pathways [14, 18, 19].
The observation of such prooxidant reactions has refined
our understanding of GGT function, whose significance ap-
pears to be dual. At a cellular level, it is conceivable that the
prooxidant effects of plasma membrane GGT are normally
balanced by its established role in favouring the cellular up-
take of precursors for GSH resynthesis, thus allowing the
maintenance of cellular antioxidant defenses. On the other
hand, the functions of soluble GGT activity in serum are less
directly related to the cellular supply of GSH, and conditions
likely exist in which its prooxidant effects may be prevailing.
The free iron required for such processes can originate from
iron storage proteins; it was in fact shown that GGT prooxi-
dant effects are sustained by both transferrin and ferritin [14,
20]. The emerging prooxidant potential of serum GGT can
help explain the recent observation that baseline serum GGT
can predict future elevations of serum F2-isoprostanes, a sen-
sitive marker of oxidative stress [21, 22]. As far as the
plaque environment, free iron is present [23], at levels suffi-
cient to sustain the GGT-mediated prooxidant effects [11].
Fig. (1). Functions of g -glutamyltransferase activity: (A) cellular supply of precursors for the resynthesis of intracellular stores of the anti-
oxidant glutathione, and (B) promotion of metal-catalyzed redox reactions, leading to the appearance of reactive oxygen species, free radicals
and oxidative modifications on proteins. (GSH), glutathione; (Cys-Gly), cysteinyl-glycine.
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CIRCULATING GGT VS. ENZYME ACTIVITY
DETECTABLE IN PLAQUES
The GGT enzyme activity circulating in serum is thought
to be mainly released from the liver [1]. Constitutively high
serum GGT has been reported in families as an inherited
autosomic dominant character, and in the apparent absence
of any disease (see e.g. [24]). Genetic effects could in princi-
ple involve either the release of GGT from liver cells or its
clearance from circulation. Other liver enzymes partly share
the same effects, and this seems to indicate that genetic fac-
tors may be operative at the level of GGT release in blood
[25]. The importance of genetic factors is still a matter for
discussion; current view is that a mixture of genetic and en-
vironmental factors can influence serum GGT [25, 26]. An-
other line of evidence points to the possibility that the source
of serum GGT may be identified in circulating platelets, as
the two parameters are usually correlated [27]. Thus, it has
been proposed that the increased GGT levels observed in
atherosclerotic patients may originate from increased platelet
consumption at the site of plaques [28].
Interestingly, serum GGT is partially adsorbed onto cir-
culating LDL [29, 30]. Details of such association were re-
cently investigated by us in a population of patients with
angiographically documented coronary artery disease (CAD)
[31]. As GGT activity in non-cholestatic patients is mainly
associated with HDL and LDL [30], the amount of GGT
activity associated with polycation-precipitated b -
lipoproteins ( b -LP) – which include LDL, intermediate den-
sity lipoprotein (IDL) and very low density lipoprotein
(VLDL), but not HDL – was assumed as an index of LDL-
associated GGT. It was thus observed that both in controls
and CAD patients the amount of GGT associated with b -LP
is directly proportional to total serum GGT levels; in CAD
patients however, the b -LP-associated fraction was signifi-
cantly lower. Furthermore, serum GGT is known to increase
with age, and such increase was indeed found in the control
group; in contrast, significantly lower total serum GGT lev-
els were detected in older CAD patients, though the ratio
between b -LP-bound and total GGT remained constant [31].
It remains to be elucidated whether this phenomenon de-
pends on the absence in CAD patients of the factor(s) elicit-
ing the increase of serum GGT with age, or rather to a selec-
tive loss of patients with higher GGT [10], due to (GGT-
related?) complications of CAD, i.e. cardiac death and
stroke.
The reasons for the association of GGT with LDL likely
lie in the peculiar structure of GGT, a dimeric protein whose
heavy chain contains the lipophilic domain responsible for
the plasma membrane insertion of the cellular enzyme. Sev-
eral proteases are capable of digesting the lipophilic domain,
thus producing a hydrophilic form of the protein [32]. The
specific association of GGT with LDL and the nature of the
protein were further confirmed by ultracentrifugation. We
found that the LDL-associated enzyme consists in an entire
heavy chain, indicating that the amphiphilic form of the en-
zyme is involved [31]. It is known however that the incuba-
tion of amphiphilic GGT with isolated lipoprotein does not
produce GGT-lipoprotein complexes [33], suggesting that
the interaction of GGT with lipoprotein may be different
from the one with plasma membrane lipids. Indeed, affinity-
adsorbed LDL released most of its GGT activity following
extensive washing, indicating a rather labile LDL/GGT asso-
ciation [31].
As the b -LP-associated fraction of GGT is proportional
to total serum GGT, the binding of GGT with LDL might
itself be related to the reported increase of cardiovascular
risk. What mechanisms could then account for the observed
decrease of b -LP-bound GGT in CAD patients, and the de-
crease of total GGT levels in older ones? Conceivably, the
reasons might be (i) a less efficient association of GGT with
LDL in these patients, (ii) an enhanced release of GGT from
LDL, or (iii) an enhanced uptake of LDL–GGT complexes
within atherosclerotic lesions, possibly of those presenting
with higher GGT contents. The latter hypothesis is particu-
larly attractive, as it would allow the integration of an overall
picture with the histochemical findings (Fig. 2): the en-
hanced uptake of LDL–GGT complexes, leading to the ap-
pearance of significant deposits of active GGT within the
lesions, might be a discrete step in atherogenesis, potentially
explaining the reported correlation between higher levels of
serum GGT and the clinical consequences of atherosclerosis.
Fig. (2). The envisaged relationships between GGT activity circu-
lating in serum in association with distinct lipoprotein fractions, and
GGT activity detectable in atherosclerotic lesions. Available data
suggest that the latter might result from the uptake of GGT/LDL
complexes within the arterial wall.
CONCLUDING REMARKS
Studies in our laboratory are currently aimed to a further
biochemical characterization of GGT present in human athe-
rosclerotic plaques. As a confirmation of the hypothesis dis-
cussed above, preliminary data indicate that the enzyme
protein accumulating in lesions has molecular weight and
chromatographic properties compatible with those of serum
GGT. In addition, proteins recovered form plaque tissue pre-
sent with some degree of S-cysteyl-glycylation, i.e. the form
of protein S-thiolation specifically catalysed by GGT [34],
thus witnessing the occurrence of prooxidant reactions pro-
moted by the accumulated enzyme [Franzini et al. manu-
script in preparation]. It seems therefore reasonable to
speculate that the prooxidant reactions promoted by GGT
activity might contribute to the (oxidative) processes in-
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volved in several aspects of plaque destabilization. Further
studies are necessary however in order to identify the factors
that favour the accumulation of GGT within plaques, and
possibly accelerate it in selected subjects.
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